First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age.

Lindgren, Line M

First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age. [electronic resource] - Vaccine 01 2017 - 596-604 p. digital

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1873-2518

10.1016/j.vaccine.2016.12.027 doi


Adjuvants, Immunologic--administration & dosage
Adolescent
Aluminum Hydroxide--administration & dosage
Antibodies, Viral--blood
Child
Child, Preschool
Denmark
Drug-Related Side Effects and Adverse Reactions--epidemiology
Female
Humans
Immunization, Secondary--methods
Infant
Male
Poliomyelitis--prevention & control
Poliovirus Vaccine, Inactivated--administration & dosage